This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. AVTE, NLTX, BIOA, CYBN, VIRI, WHWK, OSTX, ELYM, ATNM, and NBRVShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Aerovate Therapeutics (AVTE), Neoleukin Therapeutics (NLTX), BioAge Labs (BIOA), Cybin (CYBN), Virios Therapeutics (VIRI), Whitehawk Therapeutics (WHWK), OS Therapies (OSTX), Eliem Therapeutics (ELYM), Actinium Pharmaceuticals (ATNM), and Nabriva Therapeutics (NBRV). Ritter Pharmaceuticals vs. Its Competitors Aerovate Therapeutics Neoleukin Therapeutics BioAge Labs Cybin Virios Therapeutics Whitehawk Therapeutics OS Therapies Eliem Therapeutics Actinium Pharmaceuticals Nabriva Therapeutics Aerovate Therapeutics (NASDAQ:AVTE) and Ritter Pharmaceuticals (NASDAQ:RTTR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends. Is AVTE or RTTR more profitable? Ritter Pharmaceuticals' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Ritter Pharmaceuticals N/A N/A -162.05% Do insiders & institutionals hold more shares of AVTE or RTTR? 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 15.4% of Ritter Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has better earnings & valuation, AVTE or RTTR? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70-4.34Ritter PharmaceuticalsN/AN/A-$10.13MN/AN/A Which has more volatility and risk, AVTE or RTTR? Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Ritter Pharmaceuticals has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Does the media prefer AVTE or RTTR? In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled Ritter Pharmaceuticals'average media sentiment score. Company Overall Sentiment Aerovate Therapeutics Neutral Ritter Pharmaceuticals Neutral SummaryAerovate Therapeutics beats Ritter Pharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RTTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.46M$834.68M$5.82B$9.74BDividend YieldN/A4.84%3.84%4.09%P/E Ratio-2.861.1731.1525.97Price / SalesN/A26.53475.57123.18Price / CashN/A19.5637.1558.38Price / Book18.306.639.116.39Net Income-$10.13M-$4.94M$3.26B$265.66M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$1.83-2.9%N/A+810.6%$84.46MN/A-2.867AVTEAerovate TherapeuticsN/A$7.50+1.9%N/A-88.8%$217.39MN/A-2.5120Gap UpHigh Trading VolumeNLTXNeoleukin TherapeuticsN/A$20.45-0.3%N/A-45.0%$192.19MN/A-6.5890High Trading VolumeBIOABioAge LabsN/A$4.42-2.2%N/AN/A$162.04MN/A0.00N/ACYBNCybin2.5222 of 5 stars$6.59-4.8%$85.00+1,189.8%N/A$155.46MN/A-1.5050News CoverageAnalyst RevisionVIRIVirios TherapeuticsN/A$5.30+7.5%$5.00-5.7%+2,052.3%$102.07MN/A-19.635WHWKWhitehawk TherapeuticsN/A$1.65+2.5%N/AN/A$75.88M$25.98M-27.5040High Trading VolumeOSTXOS Therapies2.25 of 5 stars$2.15-1.4%$18.00+737.2%-40.0%$67.99MN/A-2.50N/AAnalyst ForecastGap UpELYMEliem TherapeuticsN/A$2.11+11.1%N/A-63.0%$62.78MN/A-3.989News CoveragePositive NewsHigh Trading VolumeATNMActinium Pharmaceuticals3.036 of 5 stars$1.65-3.5%$4.50+172.7%-19.3%$51.47MN/A-1.1930Positive NewsShort Interest ↓NBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070 Related Companies and Tools Related Companies Aerovate Therapeutics Competitors Neoleukin Therapeutics Competitors BioAge Labs Competitors Cybin Competitors Virios Therapeutics Competitors Whitehawk Therapeutics Competitors OS Therapies Competitors Eliem Therapeutics Competitors Actinium Pharmaceuticals Competitors Nabriva Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access